Synthesis and characterization of recombinant factor VIIa-conjugated magnetic iron oxide nanoparticles for hemophilia treatment

Journal of Biomedical Materials Research - Part A

Volumn 91, Issue 4, 2009, Pages 1056-1064

  Shafir, Gilead ^a   Galperin, Anna ^a   Margel, Shlomo ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Biofunctionalization; Factor VIIa; Hemophilia; Iron oxide nanoparticles; Surface modification

Indexed keywords

BIOFUNCTIONALIZATION; CHLOROMETHYL; COAGULANT ACTIVITY; CONTROLLED GROWTH; COVALENT BINDING; COVALENTLY BOUND; DIVINYL SULFONE; DOUBLE BONDS; FUNCTIONALIZATIONS; GELATIN COATINGS; HUMAN SERUM ALBUMINS; INHIBITORY EFFECT; IRON OXIDE NANOPARTICLE; MAGHEMITES; MAGNETIC IRON OXIDE NANOPARTICLES; MAGNETIC IRON OXIDES; MAGNETIC NANOPARTICLES; MICHAEL ADDITION REACTIONS; PROTEOLYTIC ENZYME; SURFACE MODIFICATION; SYNTHESIS AND CHARACTERIZATION;

ADDITION REACTIONS; BLOOD; COAGULATION; COST REDUCTION; ENZYMES; IRON ORES; IRON OXIDES; KETONES; OXIDE FILMS; RADIOACTIVITY; STABILIZATION; SURFACE TREATMENT;

NANOPARTICLES;

FERRIC OXIDE; GELATIN; NANOPARTICLE; RECOMBINANT BLOOD CLOTTING FACTOR 7A PLUS MAGNETIC IRON OXIDE NANOPARTICLE; RECOMBINANT PROTEIN; SERUM ALBUMIN; SULFONE; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; COVALENT BOND; DRUG CONJUGATION; DRUG SYNTHESIS; ENZYME IMMOBILIZATION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MICHAEL ADDITION; PLASMA HALF LIFE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN IMMOBILIZATION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; BLOOD COAGULATION; FACTOR VIIA; FERRIC COMPOUNDS; HEMOPHILIA A; MAGNETICS; NANOPARTICLES; PARTICLE SIZE; RECOMBINANT PROTEINS; SUS SCROFA; TEMPERATURE; TRYPSIN;

EID: 70450170760     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32296     Document Type: Article

References (43)

1. Butenas S, Mann KG. Blood coagulation. Biochemistry 2002;67:5-15.
2. Aitken MG. Recombinant factor VIIa. Emerg Med Australas 2004;16:446-455.
3. Jenny NS, Mann KG. Coagulation cascade: An overview. In: Loscalzo J, Schafer AI, editors. Thrombosis and Hemorrhage. Baltimore, MD: Williams and Wilkins; 1998. p 3-27.
4. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002;99:923-930. (Pubitemid 34525554)
5. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 1992;29:170-176.
6. Gistschier J, Kogan S, Diamond C, Levinson B. Genetic basis of hemophilia. Trom Haemost 1991;66:37-39.
7. McGraw RA, Davis LM, Lundblad RL, Stafford DW, Roberts HS. Structure and function of factor IX: Defects in haemophilia B. Clin Haematol 1985;14:359-383. (Pubitemid 15038456)
8. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia. Arterioscler Thromb Vasc Biol 2003;23:123-129.
9. Nilsson IM, Berntorp E, Zettervall O. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. Proc Natl Acad Sci USA 1986;83:9169-9173. (Pubitemid 17223556)
10. Nuss R, Jacobson L, Hathaway WE, Manco-Johnson M. Evidence for antiphospholipid antibodies in hemophilic children with factor VIII inhibitors. Recombinate PUP Study Group. Thromb Haemost 1999;82:1559-1560. (Pubitemid 29527660)
11. Parquet A, Laurian Y, Rothschild C, Navarro R, Guérois C, Gay V, Durin A, Peynet J, Sultan Y. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate. Thromb Haemost 1999;82:1247-1249. (Pubitemid 29473786)
12. Chaney JD, Nielsen VG. Considerations for the hemophiliac patient with inhibitors to factor VIII. Anesth Analg 2001;92:785-786. (Pubitemid 32185130)
13. Abshire T Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004;2:899-909.
14. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879-1879
15. Goodnough LT, Shander AS. Recombinant factor VIIa: Safety and efficacy. Curr Opin Hematol 2007;14:504-509. (Pubitemid 47484844)
16. Bonde C, Jensen MB. Continuous infusion of recombinant activated factor VII: Stability in infusion pump system. Blood Coagul Fibrinolysis 1998;9:103-105. (Pubitemid 28511575)
17. Lee CA, Berntrorp EE, Hoots WK, Aledort LM, editors. Textbook of Hemophilia, Chapter 40: Gene therapy: Molecular engineering of factor VIII and factor IX. Massachusetts: Blackwell Publishing; 2005. p 229-234.
18. Levi M, Peters M. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med 2005;33:883-890. (Pubitemid 40504401)
19. Goudemand J. Hemophilia. Treatment of patients with inhibitors. Cost issues. Haemophilia 1999;5:397-401.
20. Green-Sadan T, Kuttner T, Lublin-Tennenbaum T, Kinor N, Boguslavsky Y, Margel S, Yiadid G. Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquision of cacaine self-administration in rats. Exp Neurol 2005;194:97-105. (Pubitemid 40723609)
21. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Delivery Rev 2002;54:631-651.
22. Margel S, Sheichat L, Tennenbaum T. Biological glues based on thrombin conjugated nanoparticles. Patent No. PTC/IL03/00977 (2004).
23. Dordick J, Kane R, Asuri P, Karajanagi, S. Enhanced stability of proteins immobilized on nanoparticles. Patent No. PTC/US2005/031652 (2007).
24. Babes L, Denizot B, Tanguy G, Jacques J, Jenue L, Jallet P. Synthesis of iron oxide nanoparticles used as MRI contrast agents: A parametric study. J Colloid Interface Sci 1999;212:474-482. (Pubitemid 29394676)
25. Kim DK, Zhang Y, Kehr J, Klason T, Bjelke B, Muhammed M. Characterization and MRI study of surfactant-coated superparamagnetic nanoparticles administered into rat brain. J Magn Magn Mater 2001;225:256-261. (Pubitemid 32335305)
26. Hergt R, Hiergeist R, Hilger I, Kaiser WA, Lapatnikov Y, Margel S, Richter U. Maghemite nanoparticles with very high AC-losses for application in RF-magnetic hyperthermia. J Magn Magn Mater 2003;270:345-357.
27. Pardoe H, Clark PR, St Pierre TG, Moroz P, Jones SK. A magnetic resonance imaging based method for measurement of tissue iron concentration in liver arterially embolized with ferrimagnetic particles designed for magnetic hyperthermia treatment of tumors. Mag Reson Imaging 2003;21:483-488. (Pubitemid 36899080)
28. Chemla YR, Crossman HL, Poon Y, McDermott R, Stevens R, Alper MD, Clarke J. Ultrasensitive magnetic biosensor for homogeneous immunoassay. Proc Natl Acad Sci USA 2000;97:14268-14272. (Pubitemid 32016566)
29. Uhlen M. Magnetic separation of DNA. Nature 1989;340:733-734.
30. Debuire B, Chabli A, Frenoy N. Fast, manual, nonradioactive method for DNA sequencing. Clin Chem 1993;39:1682-1685. (Pubitemid 23246001)
31. Yoza B, Matsumoto M, Matsunaga T. DNA extraction using modified bacterial magnetic particles in the presence of amino silane compound. J Biotechnol 2002;94:217-224. (Pubitemid 34171627)
32. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Kruger A, Gansbacher B, Plank C. Magnetofection: Enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002;9:102-109. (Pubitemid 34189525)
33. Bergemann C, Muller-Schulte D, Oster J, A Brassard L, Lubbe AS. Magnetic ion-exchange nano- and microparticles for medical, biochemical and molecular biological applications. J Magn Magn Mater 1999;194:45-52.
34. Rudge SR, Kurtz TL, Vessely CR, Catterall LG, Williamson DL. Preparation, characterization, and performance of magnetic iron-carbon composite microparticles for chemotherapy. Biomaterials 2000;21:1411-1420.
35. Margel S, Gura S. Nucleation and growth magnetic metal oxide nanoparticles. Natural and acquired antibodies. J Biomed Mater Res 2008;85:1011-1021. (Pubitemid 351717970)
36. Ziv O, Avtalion R, Margel S. Immunogenicity of bioactive magnetic nanoparticles: Natural and acquired antibodies. J Biomed Mater Res 2008;85:1011-1021. (Pubitemid 351717970)
37. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D: App Phys 2003;36:167-181.
38. Peters T. All About Albumin: Biochemistry, Genetics and Medical Applications. San Diego, California: Academic Press; 1995. p 119.
39. Rozga M, Kloniecki M, Jablonowska A, Dadlez M, Bal W. The binding constant for amyloid Abeta40 peptide interactions with humen serum albumin. Biochem Biophys Res Commun 2007;364:714-718. (Pubitemid 350026521)
40. Tiruppahi C, Malik AB. Peptide carriers for drug delivery based on particular sequences of myeloperoxidase that serve as albumin docking proteins. Patent No. PTC/US2005/007442, 2007.
41. Berg W, Hillvarn B, Arwin H, Stenberg M, Lundstrom. The isoelecrtic point of thrombin and its behaviour compared to prothrombin at some solid surfaces. Thromb Haemost 1979;42:972-982.
42. Horak D, Krystufek M, Spevacek J. Effect of reaction parameters on the dispersion polymerization of 1-vinyl-2-pyrrolidone. J Polym Sci A: Polym Chem 2000;38:653-663. (Pubitemid 30542085)
43. Bayele HK, Murdock PJ, Perry DJ, Pasi KJ. Simple shifts in redox/thiol balance that perturb blood coagulation. FEBS Lett 2002;510:67-70.